Table 2.
Characteristics of recipients stratified for quartile of CMV doubling time.
Characteristics |
1st quartile |
2nd quartile |
3rd quartile |
4th quartile |
p-Value |
---|---|---|---|---|---|
N = 49 | N = 48 | N = 48 | N = 48 | ||
Median CMV doubling time (IQR), days | 1.7 (1.4–2.1) | 3.4 (2.9–3.9) | 5.6 (4.7–6.6) | 12.0 (9.2–21.2) | |
Median age, years (IQR) | 51 (34–62) | 47.5 (33–58) | 47 (24–57) | 45 (36–54.5) | 0.7 |
Gender (proportion of males) | 36/49 (73%) | 31/48 (65%) | 34/48 (71%) | 32/48 (67%) | 0.3 |
Median proportion of time during CMV infection on treatment (IQR) | 0.33 (0–0.75) | 0.43 (0–0.81) | 0.62 (0.21-0.85) | 0.61 (0–0.85) | 0.3 |
Type of transplantation | |||||
Proportion of SOT recipients | 22/49 (45%) | 15/48 (31%) | 15/48 (31%) | 22/48 (46%) | 0.2 |
Proportion of HSCT recipients | 27/49 (55%) | 33/48 (69%) | 33/48 (69%) | 26/48 (54%) | 0.2 |
Risk of CMV infection | |||||
Proportion at high risk | 28/49 (57%) | 20/48 (42%) | 28/48 (58%) | 20/48 (42%) | 0.2 |
Proportion at intermediary/low risk | 21/49 (43%) | 28/48 (58%) | 20/48 (42%) | 28/48 (58%) | 0.2 |
Median V1 (IQR) IU/mL | 1001 (455–3640) | 1147 (546–3076) | 915 (455–4596) | 1911 (814–14,560) | 0.02⁎ |
Median Vpeak (IQR) IU/mL | 18,200 (4186–58,240) | 5779 (1957–17,290) | 3044 (1456–12,376) | 3504 (1124–31,987) | 0.01 |
Proportion of recipients with symptomatic CMV infection1 | 22/48 (46%) | 9/46 (20%) | 14/47 (30%) | 14/47 (30%) | 0.01⁎⁎ |
Proportion of recipients with allograft rejection or GVHD | 7/49 (14%) | 9/48 (19%) | 10/48 (21%) | 10/48 (21%) | 0.4 |
For five HSCT recipients, data regarding CMV disease was unavailable.
The median V1 was not significantly different when comparing the 1st, 2nd and 3rd quartiles. The 4th quartile had a significantly higher V1 sample compared to the 1st quartile, p = 0.02.
There was a significantly higher proportion of symptomatic CMV infection when comparing the 1st quartile to the 2nd, however this was not persistent when comparing the 1st quartile to the two other quartiles (p > 0.1).